The U.S. Department of Justice’s (DOJ) lawsuit against Amedisys Inc. (NASDAQ: AMED) and UnitedHealth Group (NYSE: UNH) will ...

UnitedHealth, Amedisys and antitrust regulators will have a magistrate judge’s help in hashing out a solution to the DOJ’s ...

A federal judge in Maryland ordered the Justice Department and UnitedHealth Group to begin mediation on Aug. 18.

RBC Capital analyst Ben Hendrix maintained a Buy rating on Amedisys (AMED – Research Report) yesterday and set a price target of $100.00.Stay ...

Learn more about whether Amedisys, Inc. or BrightSpring Health Services, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Noah Tong UnitedHealth Group and Amedisys outlined plans to divest a significant number of home health and hospice locations as they seek to close their $3.3 billion merger. In a court filing ...

Amedisys, for the fourth quarter of 2024, delivers year-over-year top-line growth across three of its segments - Home Health, Hospice and High Acuity Care. While the top- and bottom-line numbers ...

Amedisys (AMED) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended March 2025. This widely-known consensus outlook gives a ...

Rating upgraded from 62 to 71 Monday — a welcome improvement, but still shy of the 80 or higher score you look for. Please ...